[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10201702396QA - Antibodies to bradykinin b1 receptor ligands - Google Patents

Antibodies to bradykinin b1 receptor ligands

Info

Publication number
SG10201702396QA
SG10201702396QA SG10201702396QA SG10201702396QA SG10201702396QA SG 10201702396Q A SG10201702396Q A SG 10201702396QA SG 10201702396Q A SG10201702396Q A SG 10201702396QA SG 10201702396Q A SG10201702396Q A SG 10201702396QA SG 10201702396Q A SG10201702396Q A SG 10201702396QA
Authority
SG
Singapore
Prior art keywords
bradykinin
antibodies
receptor ligands
ligands
receptor
Prior art date
Application number
SG10201702396QA
Inventor
Dorothea KOMINOS
Jie Zhang
Han Li
Alla Pritsker
Matthew Davison
Nicolas Baurin
Govindan Subramanian
Xin Chen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201702396Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG10201702396QA publication Critical patent/SG10201702396QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201702396QA 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands SG10201702396QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04

Publications (1)

Publication Number Publication Date
SG10201702396QA true SG10201702396QA (en) 2017-04-27

Family

ID=49261064

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201702396QA SG10201702396QA (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands
SG11201405162YA SG11201405162YA (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201405162YA SG11201405162YA (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands

Country Status (39)

Country Link
US (5) US9376494B2 (en)
EP (2) EP3246339B1 (en)
JP (4) JP6779012B2 (en)
KR (4) KR102166083B1 (en)
CN (2) CN104334578B (en)
AR (1) AR090352A1 (en)
AU (2) AU2013240242B2 (en)
BR (1) BR112014024282A2 (en)
CA (1) CA2868353C (en)
CL (2) CL2014002590A1 (en)
CO (1) CO7111293A2 (en)
CR (1) CR20140440A (en)
CY (1) CY1121466T1 (en)
DK (2) DK2831113T3 (en)
DO (1) DOP2014000199A (en)
EA (1) EA201491784A1 (en)
ES (1) ES2673869T3 (en)
GT (1) GT201400192A (en)
HK (1) HK1206754A1 (en)
HR (1) HRP20180928T1 (en)
HU (1) HUE037720T2 (en)
IL (1) IL234830B (en)
LT (1) LT2831113T (en)
MA (1) MA37407B1 (en)
MX (2) MX361874B (en)
MY (2) MY184037A (en)
NZ (1) NZ631543A (en)
PE (1) PE20142170A1 (en)
PH (1) PH12014501970A1 (en)
PL (1) PL2831113T3 (en)
PT (1) PT2831113T (en)
RS (1) RS57413B1 (en)
SG (2) SG10201702396QA (en)
SI (1) SI2831113T1 (en)
TR (1) TR201808486T4 (en)
TW (1) TWI605060B (en)
UA (1) UA117097C2 (en)
UY (1) UY34682A (en)
WO (1) WO2013148296A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201808486T4 (en) * 2012-03-28 2018-07-23 Sanofi Sa Antibodies against bradykinin B1 receptor ligands.
KR102313513B1 (en) 2013-03-13 2021-10-15 프로테나 바이오사이언시즈 리미티드 Tau immunotherapy
CN105504049B (en) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 The relevant HPV E7 protein monoclonal antibody of cervical carcinoma and its application
IL312919A (en) 2015-12-15 2024-07-01 Takeda Pharmaceuticals Co Peptide quantitation assay for differentiating fulllength high molecular weight kininogen (HMWK) and cleaved HMWK
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
EA201892417A1 (en) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед ANTIBODIES RECOGNIZING TAU
JOP20190100A1 (en) 2016-11-19 2019-05-01 Potenza Therapeutics Inc Anti-gitr antigen-binding proteins and methods of use thereof
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
CN118184781A (en) * 2017-05-08 2024-06-14 阿迪马布有限责任公司 Anti-CD 3 binding domains and antibodies comprising them and methods of their production and use
TW201945026A (en) * 2018-01-29 2019-12-01 美商希拉諾斯醫療公司 Antibodies binding ERFE and methods of use
CU20210073A7 (en) 2019-03-03 2022-04-07 Prothena Biosciences Ltd ANTIBODIES THAT BIND WITHIN THE CDRS-DEFINED MICROTUBULE-BINDING REGION OF TAU

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
ATE218889T1 (en) 1990-11-09 2002-06-15 Stephen D Gillies CYTOKINE IMMUNOCONJUGATES
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JP2001506967A (en) 1996-08-02 2001-05-29 ブリストル―マイヤーズ・スクイブ・カンパニー Methods for suppressing immunoglobulin-induced toxicity as a result of the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2002512624A (en) 1997-05-21 2002-04-23 バイオベーション リミテッド Method for producing non-immunogenic protein
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
JP2002534959A (en) 1998-12-08 2002-10-22 バイオベーション リミテッド Methods for modifying immunogenic proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ES2649037T3 (en) 2000-12-12 2018-01-09 Medimmune, Llc Molecules with prolonged half-lives, compositions and uses thereof
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
CN1705491B (en) 2002-09-27 2013-05-29 赞科股份有限公司 Optimized Fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1664116A4 (en) 2003-08-22 2009-06-03 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
JP2008504002A (en) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Neonatal Fc receptor (FcRn) binding polypeptide variants, dimeric Fc binding proteins, and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP2154157A3 (en) 2004-01-12 2010-04-28 Applied Molecular Evolution Inc. FC region variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2006019447A1 (en) 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CA2612069A1 (en) 2005-06-14 2006-12-21 Cytos Biotechnology Ag Antigen conjugates and uses thereof
US7833260B2 (en) 2006-07-20 2010-11-16 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
NZ577085A (en) * 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
EP2157937B1 (en) 2007-06-04 2017-03-22 Sequent Medical, Inc. Devices for treatment of vascular defects
SI2170389T1 (en) * 2007-06-12 2015-03-31 Ac Immune S.A. Humanized antibodies to amyloid beta
MX338395B (en) 2007-08-29 2016-04-15 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses.
DK2224954T3 (en) * 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
TR201808486T4 (en) * 2012-03-28 2018-07-23 Sanofi Sa Antibodies against bradykinin B1 receptor ligands.

Also Published As

Publication number Publication date
EP3246339B1 (en) 2019-10-09
MY166157A (en) 2018-06-06
CA2868353A1 (en) 2013-10-03
KR102166083B1 (en) 2020-10-16
AU2013240242A1 (en) 2014-10-02
MA37407A1 (en) 2016-05-31
AU2018203081A1 (en) 2018-05-24
TW201343671A (en) 2013-11-01
US9376494B2 (en) 2016-06-28
ES2673869T3 (en) 2018-06-26
US20160368976A1 (en) 2016-12-22
MX2014011688A (en) 2015-01-22
US20230399388A1 (en) 2023-12-14
EP2831113A1 (en) 2015-02-04
TWI605060B (en) 2017-11-11
NZ631543A (en) 2017-03-31
PH12014501970A1 (en) 2014-11-17
US10465002B2 (en) 2019-11-05
SI2831113T1 (en) 2018-08-31
US9879079B2 (en) 2018-01-30
PL2831113T3 (en) 2018-08-31
CN104334578B (en) 2021-10-08
KR102367723B1 (en) 2022-02-28
EP3246339A1 (en) 2017-11-22
JP2021166538A (en) 2021-10-21
HRP20180928T1 (en) 2018-07-27
JP2015513903A (en) 2015-05-18
PE20142170A1 (en) 2015-01-07
KR20200121370A (en) 2020-10-23
HUE037720T2 (en) 2018-09-28
JP2019050822A (en) 2019-04-04
MA37407B1 (en) 2018-03-30
JP7411609B2 (en) 2024-01-11
HK1206754A1 (en) 2016-01-15
MX2018015914A (en) 2021-12-08
GT201400192A (en) 2015-07-29
KR102035882B1 (en) 2019-10-24
US20180222967A1 (en) 2018-08-09
IL234830B (en) 2018-11-29
CR20140440A (en) 2014-11-17
MX361874B (en) 2018-12-18
CL2017003039A1 (en) 2018-03-16
MY184037A (en) 2021-03-17
DOP2014000199A (en) 2014-10-31
US20200115441A1 (en) 2020-04-16
AU2013240242B2 (en) 2018-02-08
JP6779012B2 (en) 2020-11-04
JP2024038036A (en) 2024-03-19
UY34682A (en) 2013-10-31
DK3246339T3 (en) 2020-01-27
CN104334578A (en) 2015-02-04
KR20220031728A (en) 2022-03-11
PT2831113T (en) 2018-06-20
SG11201405162YA (en) 2014-09-26
CO7111293A2 (en) 2014-11-10
RS57413B1 (en) 2018-09-28
JP6912441B2 (en) 2021-08-04
CL2014002590A1 (en) 2015-01-16
US20150050270A1 (en) 2015-02-19
TR201808486T4 (en) 2018-07-23
BR112014024282A2 (en) 2017-08-08
AR090352A1 (en) 2014-11-05
EP2831113B1 (en) 2018-03-14
EA201491784A1 (en) 2015-02-27
KR20150002679A (en) 2015-01-07
CN113773385A (en) 2021-12-10
UA117097C2 (en) 2018-06-25
DK2831113T3 (en) 2018-06-25
LT2831113T (en) 2018-06-25
WO2013148296A1 (en) 2013-10-03
CY1121466T1 (en) 2020-05-29
CA2868353C (en) 2023-10-31
KR20190121861A (en) 2019-10-28

Similar Documents

Publication Publication Date Title
HUS2400016I1 (en) Anti-fcrn antibodies
HRP20180928T1 (en) Antibodies to bradykinin b1 receptor ligands
IL264558A (en) Anti-il-23p19 antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
EP2844290A4 (en) Novel antibodies
EP2837685A4 (en) Anti-fgfr2 antibody
EP2826790A4 (en) Gremlin-1 antibody
HK1210186A1 (en) Anti-h7cr antibodies h7cr
PL2935330T3 (en) Anti-notch3 antibodies
HK1206610A1 (en) Fully human antibodies that bind to vegfr2 vegfr2
EP2804876A4 (en) Novel antibodies
EP2848633A4 (en) Anti-cxadr antibody
EP2811018A4 (en) ANTI-sAPPß ANTIBODY
IL235188A0 (en) Anti-pdgf-c antibodies
GB201216296D0 (en) Reversibly inhibited antibodies